Press Release Date: August 13, 2024 publicizing the MIC-Drop™ technology and partnership with IDEA Biomedical.
See the original EIN Press Release HERE.
InVivo Biosystems, a trailblazer in the biotechnology industry, has unveiled remarkable advancements in its mission to transform preclinical development. Guided by its newly appointed executive team, InVivo Biosystems is leveraging its robust foundation of patented genome editing technologies to propel innovation forward. The strong innovative commitment at InVivo Biosystems is set to dramatically enhance the speed and effectiveness of therapeutic discovery. Their latest enhancements in gene editing promise to redefine lead and target identification, ushering in a new era of breakthroughs in drug
discovery and development.
Leadership Driving Innovation
Since their appointment earlier this year, InVivo Biosystems’ leadership team has hit the ground
running, propelling the company forward with innovative advancements and strategic initiatives.
Led by Chief Executive Officer Kat McCormick, Ph.D., and Chief Financial Officer Anthony
Iverson, CPA, MBA, the team has actively sought funding to fuel new scientific innovation. Their efforts have been instrumental in positioning InVivo Biosystems at the forefront of the biotech
industry, ensuring that the company remains a leader in cutting-edge research and
development.
Meanwhile, Chief Scientific Officer Trisha Brock, Ph.D., and Vice President of Strategic
Partnerships Sarah Cheesman, Ph.D., have been driving the commercialization of InVivo Biosystems’ cutting-edge scientific capabilities. Their leadership has been pivotal in bringing the
company’s innovative solutions to market, through active representation at industry conferences
and the formation of partnerships that enhance the reach and impact of the company’s
comprehensive preclinical platform.
Introducing MIC-Drop™: A Revolutionary CRISPR Breakthrough
InVivo Biosystems is proud to introduce MIC-Drop™, a cutting-edge multiplexed CRISPR gene editing technology, to which InVivo Biosystems holds an exclusive worldwide license. This revolutionary capability enables unparalleled target identification and validation, significantly accelerating the
preclinical development process by allowing precise and simultaneous editing of multiple genes in a single CRISPR injection session. With MIC-Drop™, the time required in early-stage disease
modeling is drastically reduced, achieving actionable insights without escalating financial investment.
“MIC-Drop™ represents a quantum leap in our ability to explore complex genetic interactions
and rapidly advance therapeutic candidates,” said Kat McCormick, Ph.D., CEO at InVivo Biosystems. “By performing an array of complex genetic manipulations in one sweep, MIC-Drop empowers researchers to tackle previously insurmountable challenges in genetics and biotechnology, making it a game-changer for preclinical development and rare disease research. This innovation is a testament to our relentless pursuit of technologies that empower researchers to make faster, more informed decisions in the development of life-saving treatments.”
For more information about our latest CRISPR capability, visit
RapidGen™: Transforming Preclinical Development
Along with MIC-Drop™, InVivo Biosystems leverages a suite of advanced gene editing and
phenotypic assay technologies packaged into one end-to-end preclinical development platform,
RapidGen™.
The RapidGen™ platform offers a variety of model options with the flexibility to tailor phenotypic
assays to fit the specific preclinical discovery or development need. The RapidGen™ platform
offers both live and cell based transgenic models, paired with relevant high throughput
phenotypic assays to provide disease indications for drug discovery and development.
What sets the RapidGen™ platform apart is its ability to deliver critical insights while optimizing resource allocation. By significantly reducing the time to decision-making, RapidGen™ enables
faster progression through the drug development pipeline without necessitating higher financial investment. This resource efficiency makes RapidGen™ an invaluable tool for companies seeking to accelerate their R&D processes without compromising on quality or increasing costs.
Partnerships Fueling Innovation
InVivo Biosystems’ dedication to innovation is highlighted by its formation of partnerships with premier companies in the biotechnology industry. These collaborations have been instrumental in expanding InVivo Biosystems’ RapidGen™ platform, creating a comprehensive suite for advancing both novel and repurposed therapies. Through these alliances, InVivo Biosystems has broadened its offerings beyond live alternative models to include cell based models, providing oncologic insights and advanced drug development instrumentation.
Among their most recent and notable partnerships, InVivo Biosystems has forged a
groundbreaking alliance with IDEA Biomedical, a leader in high-content scanning and analysis. This collaboration enhances drug discovery and development by integrating IDEA Biomedical’s
state-of-the-art zebrafish imaging technology with InVivo Biosystems’ RapidGen™ platform.
This synergy improves the precision and efficiency of zebrafish-based assays, driving more robust and scalable drug discovery processes.
A Commitment to Transform Preclinical Development
InVivo Biosystems’ latest partnerships and CRISPR innovations do more than enhance value for pharmaceutical companies—they exemplify the company’s dedication to discovering
groundbreaking therapies for patients in need. By offering a high-throughput approach to
identify and validate genetic targets in a fraction of the traditional timeframe, these innovations allow potential therapies to advance from the lab to clinical trials with reduced risk. This rapid
acceleration is particularly crucial for developing new treatments for rare monogenic diseases, where time is often of the essence for patients in need of treatment. The groundbreaking MIC-
Drop™ CRISPR technology expedites the preclinical phase, facilitating faster and more efficient delivery of life-saving therapies to patients.
“We are excited to unveil our enhanced CRISPR capabilities to the scientific community,” said Trisha Brock, Ph.D., Chief Scientific Officer at InVivo Biosystems. “Our team has dedicated significant effort to developing technologies that not only push the frontiers of genetic research but also align with our mission to revolutionize preclinical development. Innovations like MIC-Drop™ reflect our commitment to precision, efficiency, and transformative impact, and we eagerly anticipate the groundbreaking discoveries they will enable.”
Join the Genetic Revolution Today
About InVivo Biosystems
InVivo Biosystems is a leading biotechnology company dedicated to advancing preclinical
development through advanced genetic tools and technologies. InVivo Biosystems aims to
make the complex world of genetics accessible and impactful, driving breakthroughs in
understanding and treating complex diseases. With a focus on precision, efficiency, and
collaboration, InVivo Biosystems is at the forefront of genetic research, providing researchers
worldwide with the tools they need to unlock the underpinnings of monogenic disease.
Contact Information
Ally Wimberly
Manager, Marketing and Sales
InVivo Biosystems
[email protected]
844-663-8749
